Hinge Health (NYSE:HNGE) Price Target Raised to $80.00

Key Points

• Citizens Jmp raised its price target on Hinge Health to $80 (from $65) with a "market outperform" rating, implying roughly a 49.7% upside from the prior close and lifting analyst momentum around the stock.
• Hinge Health posted a Q1 beat — EPS $0.45 vs. $0.12 estimate and revenue $182.3M (+47% YoY) — and management raised FY2026 revenue guidance to $798–$804M and Q2 guidance to about $194–$196M, while launching an FDA-cleared Enso migraine program.
• Insiders have been net sellers, offloading 442,670 shares (~$18.8M) in the past 90 days, though insiders still own about 18.9% and institutions like Vanguard and Tudor have recently increased stakes.

Hinge Health (NYSE:HNGE - Get Free Report) had its price target hoisted by analysts at Citizens Jmp from $65.00 to $80.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a "market outperform" rating on the stock. Citizens Jmp's target price indicates a potential upside of 49.72% from the company's previous close.

Other analysts have also recently issued research reports about the company. Wall Street Zen cut Hinge Health from a "buy" rating to a "hold" rating in a research note on Saturday. Piper Sandler reiterated an "overweight" rating on shares of Hinge Health in a research report on Wednesday. Evercore reiterated an "outperform" rating and set a $45.00 price target on shares of Hinge Health in a research report on Wednesday, April 8th. Canaccord Genuity Group set a $63.00 price target on Hinge Health in a research report on Wednesday. Finally, Barclays reiterated an "overweight" rating and set a $62.00 price target on shares of Hinge Health in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $60.13.

Hinge Health Trading Up 7.4%

NYSE HNGE traded up $3.68 on Wednesday, hitting $53.43. 2,005,318 shares of the stock traded hands, compared to its average volume of 1,183,915. The stock has a 50-day moving average of $42.20 and a 200 day moving average of $43.94. Hinge Health has a twelve month low of $30.08 and a twelve month high of $62.18. The company has a market capitalization of $4.21 billion and a P/E ratio of -4.20.

Hinge Health (NYSE:HNGE - Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.33. The firm had revenue of $182.31 million for the quarter. During the same quarter in the prior year, the firm earned $1.30 EPS. The firm's quarterly revenue was up 47.2% compared to the same quarter last year. As a group, equities research analysts expect that Hinge Health will post 0.78 earnings per share for the current year.

Insider Transactions at Hinge Health

In other Hinge Health news, President James Pursley sold 15,000 shares of the stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $42.26, for a total transaction of $633,900.00. Following the completion of the transaction, the president directly owned 732,104 shares of the company's stock, valued at approximately $30,938,715.04. This trade represents a 2.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel Antonio Perez sold 166,665 shares of the stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $40.26, for a total value of $6,709,932.90. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 442,670 shares of company stock valued at $18,786,901. Company insiders own 18.92% of the company's stock.

Hedge Funds Weigh In On Hinge Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Hinge Health by 22.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,237,839 shares of the company's stock valued at $60,753,000 after purchasing an additional 228,234 shares in the last quarter. Tudor Investment Corp ET AL boosted its stake in Hinge Health by 25.9% during the 3rd quarter. Tudor Investment Corp ET AL now owns 376,266 shares of the company's stock valued at $18,467,000 after purchasing an additional 77,464 shares in the last quarter. First Eagle Investment Management LLC bought a new position in Hinge Health during the 3rd quarter valued at $4,074,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Hinge Health by 755.1% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 27,354 shares of the company's stock valued at $1,271,000 after purchasing an additional 24,155 shares in the last quarter. Finally, Braidwell LP bought a new position in Hinge Health during the 3rd quarter valued at $44,686,000.

Hinge Health News Roundup

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Q1 results: Hinge Health reported $0.45 EPS (vs. $0.12 est.) and $182.3M revenue, +47% YoY — a clear operational beat that validates growth execution and drove the immediate market reaction. Press Release
• Positive Sentiment: Raised FY & Q2 revenue guidance: Management lifted FY2026 revenue guidance to $798M–$804M (vs. consensus ~$741M) and raised Q2 revenue guidance to ~$194M–$196M, signaling stronger-than-expected demand and giving investors a clearer path to the higher top line. Business Wire
• Positive Sentiment: Wells Fargo raised its price target to $80 and assigned an “overweight” rating — a sizeable upgrade that implies material upside vs. recent levels and can attract momentum buyers. Benzinga
• Positive Sentiment: Needham raised its target to $63 with a “buy” rating, another upgrade reinforcing analyst conviction after the quarter. Benzinga
• Positive Sentiment: Product/market expansion: Hinge Health forecasted the $798M–$804M revenue range while announcing the launch of an FDA-cleared Enso migraine program — a new clinical offering that broadens addressable market beyond musculoskeletal care and supports longer-term growth potential. Seeking Alpha
• Neutral Sentiment: Earnings call and disclosures: The Q1 2026 earnings call transcript and slide deck are available for deeper detail on margin assumptions, member metrics and go-to-market cadence; these will be important for investors modeling FCF and path to profitability. Earnings Call Transcript
• Neutral Sentiment: Market context: Coverage and momentum indicators improved ahead of and after earnings (RS rating jump noted), which can amplify intraday moves but does not change fundamentals. MSN / Market Commentary

About Hinge Health

Hinge Health NYSE: HNGE is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company's platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.